Adalid Sciences

Adalid Sciences develops lipid nanoparticle (LNP) technology for delivering nucleic acids in gene and genomic therapies. Its offering covers ionizable lipid design, customizable LNP compositions and outer shell architectures, an extensive library of pre-clinically tested LNPs, and LNP assembly instrumentation.

The company works with pharmaceutical companies, biotech start-ups and CDMOs, offering partnership arrangements and services for their programs. Target applications named on the website include protein replacement therapies (mRNA), RNAi therapeutics, gene editing, mRNA vaccines and T-cell therapeutics. The website presents both its services and its instrumentation as available.

Adalid was established in June 2024 as a spin-off from the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. Its headquarters are in Prague, Czech Republic. The website states that the team has five nationalities and over 70% PhD holders, and the careers page lists open positions.

Product: Lipid nanoparticle (LNP) delivery platform with customizable compositions, a library of pre-clinically tested LNPs, and LNP assembly instrumentation.